Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis

Table 1 Characteristics of all studies included in the meta-analysis

Ref.	Country	Type	Patients(n)	Male (%)	Median follow-up time (months)
Blay et al[26], 2021	France	RCT	85	55	6.3
Janku et al[27], 2020	American	Cohort	142	58.5	10.6
Bauer et al[31], 2022	Germany	RCT	226	61.5	7.9
Li et al[32], 2023	China	RCT	54	36	13.8